Prosecution Insights
Last updated: November 17, 2026
Application No. 18/688,400

NERVE GRAFT SYSTEMS, DEVICES, AND METHODS

Non-Final OA §103
Filed
Mar 01, 2024
Priority
Sep 08, 2021 — RE 10-2021-0119675 +4 more
Examiner
TRUONG, QUANGLONG N
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Renerva LLC
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
519 granted / 660 resolved
+18.6% vs TC avg
Strong +23% interview lift
Without
With
+23.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
52 currently pending
Career history
720
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Status of Application The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant amendment to claim 1 and the arguments have been fully considered and is persuasive. The restriction requirement is withdrawn. Claims 1, 2, 4, 5, 12, 14, 15, 19, 20, 24, 32-34, and 37-43 are included in the prosecution. Claim Rejections – 35 U.S.C. 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 2, 4, 5, 12, 14, 15, 19, 20, 24, 32-34, and 37-43 are rejected under 35 U.S.C. 103 as being unpatentable over Hodde et al. (US20080107750A1) hereafter Hodde in view of Simpson et al. (US20120221025A1) hereinafter Simpson. Regarding claims 1, 2, 4, 5, 12, 14, 15, 19, 20, 24, 32-34, and 37-43, Hodde is drawn to methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use (abstract). Hodde discloses a method for manufacturing a tissue graft material such as a collagenous extracellular matrix containing at least one extractable, bioactive growth factor or other non-collagenous protein material, particularly Fibroblast Growth Factor-2 (FGF-2), at a predetermined amount. The method includes the steps of providing a non-sterile extracellular matrix material; fashioning a plurality of graft products from the extracellular matrix material; packaging the products; subjecting the packaged products to a sterilization procedure that affects the level of extractable bioactive growth factor (FGF-2) or other non-collagenous protein material in the products; and, taking and testing sample products of the sterilized packaged products to determine a level of a growth factor (FGF-2) in the sample products, wherein said determined level is representative of an approximate level of said growth factor in other ones of said products from the lot from which the sample product was taken [0005]. Hodde does not explicitly disclose the presence of nerve tissue. However, Simpson is drawn to electrospun fibers are oriented parallel to the long axis of the guide, and gaps and elongated spaces between the stacked fiber arrays provide channels for directed axonal growth. In some embodiments, the nerve guides also comprise high precision gradients of beneficial substances such as growth factors, which aid in nerve regeneration and growth along the guide (abstract). Simpson discloses nerve guides formed from electrospun fibers for use in the directed regeneration of damaged or severed peripheral nerves. The technique of static air-gap electrospinning is used to generate cylindrical, seamless three dimensional (3D) arrays of highly aligned electrospun fibers oriented in parallel with the long axis of the construct. The air-gap technique allows the fabrication of cylinders of aligned fibers without “rolling” a sheet of fibers, and thus no potentially weakening or irregular seams or inordinately large “pores” are present in the guide, and the guide does not contain a “hollow” central channel. Instead, the guide comprises multiple open channels formed by elongated gaps between the fibers, and the channels are lined with aligned fibers that are oriented along the long axis of the guide and bounded by elongated, oriented fibers. The fibers of these structures are integrated on a true nano-scale. And, unlike other nerve guides that may contain hundreds to thousands of channels that are designed to support axon regeneration. A similar sized electrospun 3D nerve guide (depending on its size and fiber characteristics) produced by air gap electrospinning may contain hundreds of thousands to tens of millions of individual channels, each of which is “lined” with nano-to-micron scale diameter fibers that are designed to provide guidance cues [0018]. However, it would have been obvious to one of ordinary skill in the art at the time the invention was made to modify the teachings of Hodde, wherein fibers are nerve guides, as previously disclosed by Simpson, and arrive and the instant invention. One of ordinary skill in the art would have been motivated to do so because Hodde and Simpson are both in the field of extracellular tissue devices, and Simpson discloses the nerve guides also comprise high precision gradients of beneficial substances such as growth factors, which aid in nerve regeneration and growth along the guide (abstract). Further, one having ordinary still in the art would reasonably expect success in combining prior art elements according to known methods to yield predictable results, see MPEP 2141. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QUANGLONG N TRUONG whose telephone number is (571)270-0719. The examiner can normally be reached on 8:00 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /QUANGLONG N TRUONG/Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Mar 01, 2024
Application Filed
Aug 11, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788850
A Drug Coating Formulation for a Sirolimus Coated Balloon Catheter
2y 7m to grant Granted Nov 10, 2026
Patent 12788717
MAGNETIC FERRITIC NANOCOMPOSITE
2y 0m to grant Granted Nov 10, 2026
Patent 12773486
PROCESS FOR REMOVING IONS FROM BODILY FLUIDS USING SMALL MOLECULE METAL CHELATORS AND METALLATE ION EXCHANGE COMPOSITIONS
5y 2m to grant Granted Oct 27, 2026
Patent 12773439
BOTANICAL EXTRACTION
3y 7m to grant Granted Oct 27, 2026
Patent 12765545
PREPARATION OF A DRY BIOMASS EXTRACT RICH IN POLYPHENOLS
3y 11m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+23.2%)
Low
PTA Risk
Based on 660 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month